|Test Code||TELOU / NTXPR-M|
|Methodology||Vitros ECi Competitive Assay
|Description||Useful for identifying individuals with elevated bone resorption, who have osteoporosis in whom response to treatment is being monitored; for predicting response (as assessed by bone mass measurements) to FDA-approved anti-resorptive therapy in postmenopausal women; and for assessing effectiveness of osteoporosis treatment including FDA-approved anti-resorptive therapies in postmenopausal women, individuals with osteoporosis, Paget's disease of bone, and anti-estrogen or selective estrogen therapies.
NOTE: This test, when ordered on Medicare patients, is subject to the National Coverage Determination (NCD) policy "Collagen Crosslinks, Any Method". Please verify that the diagnosis code (ICD-9) you have chosen demonstrates medical necessity for the test as documented in the physician's patient record. The CMS web site or the NorDx Medical Necessity Reference Guide are available to assist you with this verification. A properly executed Advance Beneficiary Notice (ABN) must be submitted with the specimen if medical necessity is not demonstrated by the ICD-9 code chosen or if the frequency of a frequency-limited test is unknown.
|Specimen||SUBMIT ONLY 1 OF THE FOLLOWING:
SECOND-MORNING VOIDED (2-HOUR) URINE
|Reference Values||All units are reported in nmol NTx/mmol creatinine
<6 years: 576-1763
> or =6 years-14 years: 307-1367
> or =14 years-18 years: 102-1048
> or =18 years: 21-66
Based on Mayo in-house studies of 75 children and adolescents age 3.5 to 18.5, and >100 adults.
|Analytic Time||1 Day|
|Day(s) Test Set Up||Sunday through Friday|